Therapy Areas: Inflammatory Diseases
Assertio Holdings completes Zyla Life Sciences merger
21 May 2020 -

Assertio Holdings Inc, the successor issuer to Assertio Therapeutics Inc (NASDAQ: ASRT), has completed the merger with Zyla Life Sciences, it was reported on Wednesday.

The integrated company is to operate under the Assertio name and trade on Nasdaq under the ticker ASRT. The companies say that the merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products.

The merged company has a board composed of nine directors. Six directors from the pre-merger Assertio board, including Arthur Higgins, the non-executive chairman, Heather L Mason, William T McKee, Peter D Staple, James L Tyree and David E Wheadon and Todd N Smith, Timothy P Walbert, the lead independent director, and Andrea Heslin Smiley joined from the Zyla board.

Login
Username:

Password: